Safety of deferasirox as an oral iron chelator in thalassemic children
نویسندگان
چکیده
منابع مشابه
Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
OBJECTIVE Many patients with transfusional iron overload are at risk for progressive organ dysfunction and early death and poor compliance with older chelation therapies is believed to be a major contributing factor. Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake. METHODS The prospective, open-label, 1-yr ESCALAT...
متن کاملDeferasirox: a novel, once-daily oral iron chelator
10.1586/14750708.3.4.453 © 2 Regular blood transfusions for the treatment of chronic anemia inevitably lead to iron overload since humans do not possess a physiological mechanism for removing excess iron. Without appropriate treatment, the cumulative effects of iron overload lead to severe organ damage and, ultimately, death. The iron chelating agent, deferoxamine, has been used effectively for...
متن کاملEffects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
AIM To evaluate the inhibitory effects of deferasirox (DFX) against hepatocellular carcinoma (HCC) through basic and clinical studies. METHODS In the basic study, the effect of DFX was investigated in three hepatoma cell lines (HepG2, Hep3B, and Huh7), as well as in an N-nitrosodiethylamine-induced murine HCC model. In the clinical study, six advanced HCC patients refractory to chemotherapy w...
متن کاملDeferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
Although sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC) recurrence, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator, deferoxamine can prevent liver fibrosis and preneoplastic lesions. We investigated the influence of administering a new oral iron chelator, deferasi...
متن کاملImmunological evaluation of β-thalassemia major patients receiving oral iron chelator deferasirox.
OBJECTIVE To determine the immune abnormalities and occurrence of infections in transfusion-dependent β-thalassemia major patients receiving oral iron chelator deferasirox (DFX). STUDY DESIGN An observational study. PLACE AND DURATION OF STUDY Hematology Clinics, King Khalid University Hospital, Riyadh, Saudi Arabia, from July to December 2010. METHODOLOGY Seventeen patients with β-thalas...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Basic and Clinical Pharmacology
سال: 2016
ISSN: 2319-2003
DOI: 10.18203/2319-2003.ijbcp20161483